<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="iso-abbrev">An Bras Dermatol</journal-id>
      <journal-title-group>
        <journal-title>Anais Brasileiros de Dermatologia</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0365-0596</issn>
      <issn pub-type="epub">1806-4841</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Dermatologia</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">25387517</article-id>
      <article-id pub-id-type="pmc">4230681</article-id>
      <article-id pub-id-type="doi">10.1590/abd1806-4841.20143257</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Communication</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Two cases of renal cell cancer during immunobiologic therapy for
psoriasis<xref ref-type="fn" rid="fn01">*</xref>
</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Zarur</surname>
            <given-names>Fabiana Palmieri</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
          <xref ref-type="corresp" rid="c01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>d'Almeida</surname>
            <given-names>Luiza Ferreira Vieira</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mafort</surname>
            <given-names>Monique Samy Pamplona</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>de Gusm&#xE3;o</surname>
            <given-names>Paula Regazzi</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Avelleira</surname>
            <given-names>Jo&#xE3;o Carlos Regazzi</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
        <aff id="aff01"><label>1</label> Instituto de Dermatologia Prof. Rubem David Azulay - Santa Casa da
Miseric&#xF3;rdia do Rio de Janeiro (IDPRDA - SCMRJ) - Rio de Janeiro (RJ), Brazil.</aff>
      </contrib-group>
      <author-notes>
        <corresp id="c01"><italic>MAILING ADDRESS:</italic> Fabiana Palmieri Zarur, Rua Guimar&#xE3;es Rosa 203 apto
705 - Barra da Tijuca, 22793-620 - Rio de Janeiro - RJ, Brazil. E-mail:
<email>fabianazarur@hotmail.com</email></corresp>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <season>Nov-Dec</season>
        <year>2014</year>
      </pub-date>
      <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
        <season>Nov-Dec</season>
        <year>2014</year>
      </pub-date>
      <volume>89</volume>
      <issue>6</issue>
      <fpage>1017</fpage>
      <lpage>1018</lpage>
      <history>
        <date date-type="received">
          <day>08</day>
          <month>11</month>
          <year>2013</year>
        </date>
        <date date-type="accepted">
          <day>19</day>
          <month>11</month>
          <year>2013</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution Non-Commercial License which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Immunobiologic therapy is indicated for severe forms of psoriasis, resistant to
conventional therapy. There is growing concern about their safety profile and
possible association with cancer development. This article documents two cases of
renal cell cancer during treatment with biologic therapy, reviewing what is described
in the literature . The risk of solid tumors as a complication of using TNF-alpha
inhibitors is controversial. No conclusion can be drawn from the data in the
literature, however, we believe that special attention should be given to those with
known risk factors for a specific neoplasm.</p>
      </abstract>
      <kwd-group>
        <kwd>Biological therapy</kwd>
        <kwd>Kidney neoplasms</kwd>
        <kwd>Psoriasis</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <p>Psoriasis is a chronic autoimmune disease that affects the skin and joints, with worldwide
prevalence ranging from 0.8 to 4.6%.<sup><xref rid="r01" ref-type="bibr">1</xref></sup> A
large number of topical and systemic treatments are available, and immunobiologic therapy
is indicated for moderate to severe resistant forms, or individuals for whom conventional
therapy is contraindicated. However, there is a growing concern about the safety profile,
mainly due to the possible association of these drugs with an increased incidence of
neoplasia. This article documents two cases of renal cell cancer during treatment with
biologic therapy, reviewing the literature so far.</p>
    <p>The first case concerns a 41-year-old man with eleven years of severe psoriasis and
psoriatic arthritis (polyarticular and axial involvement). His level on the Psoriasis Area
and Severity Index (PASI) remained at 28.9 despite taking methotrexate (MTX). Infliximab
4mg/kg was thus added to existing therapy and he responded excellently. After a year of
treatment, the calculated PASI was 1.8. At one hundred and eight weeks of infliximab,
hepatitis was diagnosed due to the development of jaundice and elevated transaminase
levels. An abdominal ultrasound was requested, which revealed a mass in the right kidney.
After a urology evaluation, a total nephrectomy was performed with a diagnosis of clear
cell renal carcinoma by histopathological analysis. The surgery was curative and
administration of leflunomide 10mg/day stabilized joint symptoms and partially controlled
the cutaneous lesions.</p>
    <p>The following report concerns a 66 year-old-man with a 40-year history of psoriasis. He had
already used MTX and was undergoing psoralen in addition to UVA light therapy (PUVA)
treatment twice a week, and taking acitretin 30mg once a day. Despite the instituted
therapy, new cutaneous lesions and joint symptoms appeared, leading consequently to the
initiation of etanercept at a dose of 50mg per week. He achieved disease control with
resolution of the joint symptoms and a decline in PASI of more than 90%. After two hundred
and eighteen weeks of therapy, prostatic symptoms led to an abdominal ultrasonography. In
this case, a renal mass was also found and the patient underwent a total nephrectomy, whose
histopathological examination revealed papillary renal carcinoma. Surgery was also
curative, and the patient kept the disease under control with 30mg/day of acitretin.</p>
    <p>Renal cell carcinoma accounts for 3% of all malignancies, is twice as common in men and the
age group 50-70 years is the most affected.<sup><xref rid="r02" ref-type="bibr">2</xref></sup> The most common histologic type is clear cell carcinoma (75-85%)
followed by papillary (10-15%), chromophobe (5-10%), oncocytic (3-7%) and collecting duct
(&lt;1%).<sup><xref rid="r03" ref-type="bibr">3</xref></sup> Since it is a silent
cancer, the increased availability and improvement of imaging methods have led to a large
increase in the percentage of incidental renal tumors, with 50% classified as
incidentalomas.<sup><xref rid="r04" ref-type="bibr">4</xref></sup></p>
    <p>Data on the risk of solid tumors as a complication of using TNFa (Tumor necrosis factor
alpha) inhibitors are controversial. A study in Sweden with three cohorts found that the
risk of solid malignancies in patients with rheumatoid arthritis treated with TNFa
inhibitors is not greater than what would be expected with the disease alone.<sup><xref rid="r05" ref-type="bibr">5</xref></sup> A meta-analysis of 63 studies, including a
total of 29,423 patients, found no significant risk among those undergoing biologic
therapy, compared with disease-modifying drugs or placebo, with a follow-up of at least 24
weeks.<sup><xref rid="r06" ref-type="bibr">6</xref></sup> However, a double-blind,
randomized study, showed increased risk of solid tumors in patients with Wegener's
granulomatosis treated with TNFa inhibitors and cyclophosphamide, compared with those
treated only with cyclophosphamide.<sup><xref rid="r07" ref-type="bibr">7</xref></sup> Do
TNFa inhibitors increase the chance of solid tumors, such as renal neoplasia? Or have they
been overdiagnosed due to advances in imaging methods, leading to bias in studies?</p>
    <p>In the specific case of renal cell carcinoma, few reports showed renal neoplasia in
patients undergoing immunobiologic therapy. Some authors studied the benefit of TNFa
inhibitors as an adjunctive therapy in treating these tumors, based on the fact that TNFa
receptors were found in neoplasic renal cells.<sup><xref rid="r08" ref-type="bibr">8</xref></sup> We have found evidence in the literature that patients with psoriasis
have an increased incidence of lymphoproliferative disorders, particularly Hodgkin's
lymphoma and cutaneous T-cell lymphoma.<sup><xref rid="r09" ref-type="bibr">9</xref></sup>
There is also a higher risk of solid tumors, and associated characteristics include the use
of oral medication (gravity indicators) and long duration of disease (&gt; 4
years).<sup><xref rid="r10" ref-type="bibr">10</xref></sup></p>
    <p>TNFa inhibitors are associated with potentially serious adverse effects. However, these
risks must be interpreted in the context of the potential benefits associated with such
products.</p>
    <p>The adverse effects of conventional treatments, including the risk of inducing malignancy,
are also significant in most cases. Thus, the decision to use a TNF inhibitor should be
individual, based on the specific clinical characteristics and specific risk profile of a
particular patient.</p>
    <p>With respect to the patients described above, we cannot draw conclusions from the data
found in the literature regarding the development of renal cancer with the instituted
therapy. However, we believe that special attention should be given to those with known
risk factors for a specific neoplasm, who use these medications.</p>
  </body>
  <back>
    <fn-group>
      <fn fn-type="conflict">
        <p>Conflict of interest: None</p>
      </fn>
      <fn fn-type="financial-disclosure">
        <p>Financial funding: None</p>
      </fn>
      <fn fn-type="other">
        <p>How to cite this article: Zarur FP, d'Almeida LFV, Mafort M, Gusm&#xE3;o PR, Avelleira
JCR. Two cases of renal cell cancer during immunobiologic therapy for psoriasis. An
Bras Dermatol. 2014;89(6):1017-8.</p>
      </fn>
      <fn id="fn01" fn-type="other">
        <label>*</label>
        <p> Work performed at the Instituto de Dermatologia Prof. Rubem David Azulay- Santa Casa
da Miseric&#xF3;rdia do Rio de Janeiro (IDPRDA - SCMRJ) - Rio de Janeiro (RJ), Brazil.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="r01">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Naldi</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Epidemiology of psoriasis</article-title>
          <source>Curr Drug Targets Inflamm Allergy</source>
          <year>2004</year>
          <volume>3</volume>
          <fpage>121</fpage>
          <lpage>128</lpage>
          <pub-id pub-id-type="pmid">15180464</pub-id>
        </element-citation>
      </ref>
      <ref id="r02">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Figlin</surname>
              <given-names>RA</given-names>
            </name>
          </person-group>
          <article-title>Renal cell carcinoma: management of advanced disease</article-title>
          <source>J Urol</source>
          <year>1999</year>
          <volume>161</volume>
          <fpage>381</fpage>
          <lpage>386</lpage>
          <pub-id pub-id-type="pmid">9915408</pub-id>
        </element-citation>
      </ref>
      <ref id="r03">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>St&#xF6;rkel</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>van den Berg</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Morphological classification of renal cancer</article-title>
          <source>World J Urol</source>
          <year>1995</year>
          <volume>13</volume>
          <fpage>153</fpage>
          <lpage>158</lpage>
          <pub-id pub-id-type="pmid">7550386</pub-id>
        </element-citation>
      </ref>
      <ref id="r04">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Landis</surname>
              <given-names>SH</given-names>
            </name>
            <name>
              <surname>Murray</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Bolden</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Wingo</surname>
              <given-names>PA</given-names>
            </name>
          </person-group>
          <article-title>Cancer statistics, 1999</article-title>
          <source>CA Cancer J Clin</source>
          <year>1999</year>
          <volume>49</volume>
          <fpage>8</fpage>
          <lpage>31</lpage>
          <page-range>8-31,1</page-range>
          <pub-id pub-id-type="pmid">10200775</pub-id>
        </element-citation>
      </ref>
      <ref id="r05">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Askling</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Fored</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Brandt</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Baecklund</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Bertilsson</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Feltelius</surname>
              <given-names>N</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Risks of solid cancers in patients with rheumatoid arthritis and after
treatment with tumour necrosis factor antagonists</article-title>
          <source>Ann Rheum Dis</source>
          <year>2005</year>
          <volume>64</volume>
          <fpage>1421</fpage>
          <lpage>1426</lpage>
          <pub-id pub-id-type="pmid">15829572</pub-id>
        </element-citation>
      </ref>
      <ref id="r06">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lopez-Olivo</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Tayar</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Martinez-Lopez</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Pollono</surname>
              <given-names>EN</given-names>
            </name>
            <name>
              <surname>Cueto</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Gonzales-Crespo</surname>
              <given-names>MR</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Risk of Malignancies in Patients whith rheumathoid arthritis treated
with biologic therapy: a meta-analysis</article-title>
          <source>JAMA</source>
          <year>2012</year>
          <volume>308</volume>
          <fpage>898</fpage>
          <lpage>908</lpage>
          <pub-id pub-id-type="pmid">22948700</pub-id>
        </element-citation>
      </ref>
      <ref id="r07">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stone</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Holbrook</surname>
              <given-names>JT</given-names>
            </name>
            <name>
              <surname>Marriott</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Tibbs</surname>
              <given-names>AK</given-names>
            </name>
            <name>
              <surname>Sejismundo</surname>
              <given-names>LP</given-names>
            </name>
            <name>
              <surname>Min</surname>
              <given-names>YI</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Solid Malignancies Among Patients in the Wegner's Granulomatosis
Etanercept Trial</article-title>
          <source>Arthritis Rheum</source>
          <year>2006</year>
          <volume>54</volume>
          <fpage>1608</fpage>
          <lpage>1618</lpage>
          <pub-id pub-id-type="pmid">16646004</pub-id>
        </element-citation>
      </ref>
      <ref id="r08">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Harrison</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Obermueller</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Maisey</surname>
              <given-names>NR</given-names>
            </name>
            <name>
              <surname>Hoare</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Edmonds</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>NF</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Tumor Necrosis Factor &#x3B1; as a new target for renal cell carcinoma: two
sequential Phase IItrials of Infliximab at standart and high dose</article-title>
          <source>J Clin Oncol</source>
          <year>2007</year>
          <volume>25</volume>
          <fpage>4542</fpage>
          <lpage>4549</lpage>
          <pub-id pub-id-type="pmid">17925549</pub-id>
        </element-citation>
      </ref>
      <ref id="r09">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gelfand</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Shin</surname>
              <given-names>DB</given-names>
            </name>
            <name>
              <surname>Neimann</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Margolis</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Troxel</surname>
              <given-names>AB</given-names>
            </name>
          </person-group>
          <article-title>The risk of lymphoma in patients with psoriasis</article-title>
          <source>J Invest Dermatol</source>
          <year>2006</year>
          <volume>126</volume>
          <fpage>2194</fpage>
          <lpage>2201</lpage>
          <pub-id pub-id-type="pmid">16741509</pub-id>
        </element-citation>
      </ref>
      <ref id="r10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brauchli</surname>
              <given-names>YB</given-names>
            </name>
            <name>
              <surname>Jick</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Miret</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Meier</surname>
              <given-names>CR</given-names>
            </name>
          </person-group>
          <article-title>Psoriasis and Risk of Incident Cancer: An Inception Cohort Study with
a Nested Case-Control Analysis</article-title>
          <source>J Invest Dermatol</source>
          <year>2009</year>
          <volume>129</volume>
          <fpage>2604</fpage>
          <lpage>2612</lpage>
          <pub-id pub-id-type="pmid">19440219</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
